For example, therapeutic approaches based on tumor vaccines or chimeric antigen receptor (CAR) T-cell therapies targeting fibroblast activation protein (FAP), a surface marker of CAF, have been shown to reactivate antitumor immune responses and inhibit tumor progression (44, 45). The gene discussed is FAP; the disease is neoplasm.